Want to see OCGN full AI Analyst Report?
OCGN Stock Chart & Stats
$1.99
-$0.04(-4.99%)
At close: 4:00 PM EST
$1.99
-$0.04(-4.99%)
Day’s Range― - ―
52-Week Range$0.93 - $2.73
Previous CloseN/A
Volume1.89M
Average Volume (3M)8.19M
Market Cap
$463.77M
Enterprise Value$594.30
Total Cash (Recent Filing)$31.86M
Total Debt (Recent Filing)$33.30M
Price to Earnings (P/E)―
Beta1.11
Next Earnings
Jul 31, 2026EPS Estimate
-0.05Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.24
Shares Outstanding338,521,850
10 Day Avg. Volume4,577,911
30 Day Avg. Volume8,188,017
Financial Highlights & Ratios
PEG Ratio-0.39
Price to Book (P/B)-33.31
Price to Sales (P/S)91.83
P/FCF Ratio-7.09
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$9.67Price Target Upside385.76% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-0.22
Revenue Forecast (FY)$4.37M
Bulls Say, Bears Say
Bulls Say
Late‑stage Pipeline ProgressionCompletion of pivotal enrollments and statistically positive 12‑month Phase 2 data meaningfully de‑risks development. Late‑stage progress raises the probability of BLA submissions and regulatory milestones in the next 2–3 years, enabling clearer commercial planning, partner monetization and milestone realization.
International Licensing StrategyThe MENA licensing term sheet shows a repeatable external commercialization pathway that generates near‑term non‑dilutive cash and long‑term royalty upside. Partnering for regional rights sustainably broadens market access, shares execution risk, and provides milestone visibility supportive of program economics.
Extended Funded RunwayThe convertible note financing refilled liquidity and retired higher‑cost debt, extending cash runway into 2028. This funded runway supports completion of late‑stage trials, regulatory filings and manufacturing scale‑up, materially reducing near‑term refinancing risk and enabling execution of strategic development milestones.
Bears Say
Weak Operating Cash GenerationConsistent negative operating and free cash flow indicates structural cash burn that necessitates ongoing external funding. This limits the company's ability to self‑fund development, increases reliance on dilutive financings or costly debt, and constrains long‑term strategic flexibility absent product revenues.
Stressed Balance Sheet And LeverageRising debt and a negative equity balance erode the capital cushion and elevate refinancing, covenant and interest burdens. Structural leverage reduces financial flexibility to invest in commercialization or manufacturing, heightens default risk under adverse conditions, and raises the probability of distressed financing.
Convertible Issuance Dilution RiskThe convertible notes introduce potential long‑term dilution and capital‑structure complexity if conversions occur. Conversion or settlement terms create an overhang that can dilute existing holders, affect governance dynamics, and complicate future equity raises or partner negotiations as conversion thresholds are met.
Ocugen News
OCGN FAQ
What was Ocugen Inc’s price range in the past 12 months?
Ocugen Inc lowest stock price was $0.93 and its highest was $2.73 in the past 12 months.
What is Ocugen Inc’s market cap?
Ocugen Inc’s market cap is $463.77M.
When is Ocugen Inc’s upcoming earnings report date?
Ocugen Inc’s upcoming earnings report date is Jul 31, 2026 which is in 12 days.
How were Ocugen Inc’s earnings last quarter?
Ocugen Inc released its earnings results on May 05, 2026. The company reported -$0.06 earnings per share for the quarter, missing the consensus estimate of -$0.051 by -$0.009.
Is Ocugen Inc overvalued?
According to Wall Street analysts Ocugen Inc’s price is currently Undervalued.
Does Ocugen Inc pay dividends?
Ocugen Inc does not currently pay dividends.
What is Ocugen Inc’s EPS estimate?
Ocugen Inc’s EPS estimate is -0.05.
How many shares outstanding does Ocugen Inc have?
Ocugen Inc has 338,521,850 shares outstanding.
What happened to Ocugen Inc’s price movement after its last earnings report?
Ocugen Inc reported an EPS of -$0.06 in its last earnings report, missing expectations of -$0.051. Following the earnings report the stock price went down -19.459%.
Which hedge fund is a major shareholder of Ocugen Inc?
Currently, no hedge funds are holding shares in OCGN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Ocugen Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$9.67 (385.76% Upside)
$9.67 (385.76% Upside)
Blogger Sentiment
Bullish
OCGN Sentiment 70%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Increased
By 3.5M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $25.8K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▼ 0.9%
Last 30 Days ▼ 0.2%
Last 30 Days ▼ 0.2%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
36.00%
12-Months-Change
Fundamentals
Return on Equity
-9999.00%
Trailing 12-Months
Asset Growth
-11.72%
Trailing 12-Months
Company Description
Ocugen Inc
Ocugen, Inc. is a biopharmaceutical company in the clinical development phase, primarily dedicated to pioneering gene therapies aimed at treating various ophthalmic conditions leading to blindness. The company's developmental pipeline features several key candidates: OCU400: An innovative gene therapy designed to reinstate both the function and structural integrity of the retina across a broad spectrum of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and Leber congenital amaurosis. OCU410: Another gene therapy candidate, currently being developed to address dry age-related macular degeneration (AMD). OCU200: A novel fusion protein, presently undergoing preclinical evaluation for its potential in treating diabetic macular edema, diabetic retinopathy, and wet AMD. Ocugen maintains significant strategic collaborations, including a partnership with CanSino Biologics Inc. for the joint development and manufacturing of gene therapies, and an alliance with Bharat Biotech for the commercialization of COVAXIN within the United States market. The company's corporate headquarters are situated in Malvern, Pennsylvania.
OCGN Stock 12 Month Forecast
Average Price Target
$9.67
▲(385.76% Upside)
Technical Analysis
Sinovac Biotech
―
XOMA Royalty Corporation
―
ADC Therapeutics
―
Monte Rosa Therapeutics
―
AbSci
―
Ownership Overview
2.65% Insiders
5.46% Mutual Funds
0.97% Other Institutional Investors
76.08% Public Companies and
Individual Investors